Navigation Links
Trial of VivaGel in Sexually Active Young Women Commences

Starpharma Holdings Limited announced the commencement in the U.S. of a trial to assess the safety and acceptability of SPL7013 Gel (VivaGel(TM)) in sexually active young women.

The Microbicide Trials Network (MTN) is leading the study, funded by the U.S. National Institutes of Health (NIH), in which VivaGel(TM) will be tested for the first time in sexually active young women to determine its safety, acceptability and ease of use. VivaGel(TM) is being developed as a vaginal microbicide for the prevention of HIV and genital herpes.

The expanded safety study is being conducted at the University of South Florida in Tampa, Florida, and the University of Puerto Rico in San Juan, Puerto Rico, through a collaboration between the MTN (an HIV/AIDS clinical trials network established by the National Institute of Allergy and Infectious Diseases, NIH), the Adolescent Medicine Trials Network for HIV/AIDS Interventions (of the National Institute of Child Health and Human Development, NIH), and Starpharma.

Nearly 50 percent of people infected with HIV/AIDS today are women and most of them become infected through sexual intercourse with male partners. Women under the age of 25 are particularly at risk of infection.

"We have already conducted clinical trials on the safety of VivaGel(TM) in sexually inactive women and men, but this is the first time the product will be used in sexually active young women, one of our target populations. This study, in addition to the usual safety data, will collect valuable information regarding the product's use and acceptability in the consumer setting," said Dr Jackie Fairley, Chief Executive Officer of Starpharma.

"The data from this trial will provide information of value to the development of VivaGel(TM) for all indications, including preventing the spread of genital herpes," added Dr Fairley.

The study will enroll 40 sexually active, HIV-negative women aged 18 t
'"/>




Page: 1 2

Related medicine news :

1. Results Of Human Trials Of Hungarian Bird-Flu Vaccine Expected Today
2. Vaccine For Dengue Fever On Trial In Asia-Pacific
3. DNA Vaccine Trials Against HIV Virus In Sweden Nurture Hope
4. Clinical Trials of New Drug Febuxostat Show Promise in Gout Treatment
5. Sex, Race Influence Lung Cancer Trial Participation
6. Clinical Trials Of New Anti-Cancer Drug To Be Initiated In New Zealand
7. Diarrhea Vaccine Trials Promises Prevention of Rotavirus Infection
8. New Generation Clinical Trials Could Save Time And Money, Improve Patient Care
9. China Begins Human Trials For HIV/AIDS Drug
10. Patients Should Be Entitled to "Humane Compensation" if Drug Trials Go Wrong
11. HIV/AIDS Vaccine Trial To Be Initiated Soon
Post Your Comments:
(Date:10/3/2008)...- Inc. Magazine recently included,Connolly Consult...ing,private companies in the country. The list is ...segment of the economy -- America,s,independent-mi...ies,represent the backbone of the U.S. economy., ...03/NY36880LOGO ), Connolly Consulting,s consiste...
(Date:10/3/2008)... Discrimination; Recognizes,Importance of Mental H.../PRNewswire-USNewswire/ -- Mental Health,America t...approval of a,mental health parity legislation tha...ion against Americans with mental health and subst...lans., The legislation, which recognizes the impo...
(Date:10/3/2008)...search Foundation(R) Collection of, Bouquets to T...Research, LOS ANGELES, Oct. 3 /PRNewswire/ -- Tel...g only hand-arranged, hand-delivered floral,arrang...nth-long,collaboration with The City of Hope, John... Cancer Center in southern California and national...
(Date:10/3/2008)...- As the population ages, a big,question employers...e the,financial crunch of an illness?", In most c...eck to,paycheck and now need two incomes to provid... spouses becomes critically ill and unable to work...ut the healthy,employee/spouse is strained by the ...
Breaking Medicine News(10 mins):Health News:Connolly Consulting Makes the 2008 Inc. Magazine's List of America's 5000 Fastest Growing Companies 2Health News:Mental Health America Hails Approval of Federal Parity Legislation 2Health News:Mental Health America Hails Approval of Federal Parity Legislation 3Health News:Teleflora and Nationally Recognized Hospitals to Honor Women Battling Breast Cancer 2Health News:Teleflora and Nationally Recognized Hospitals to Honor Women Battling Breast Cancer 3Health News:Can Your Employees Survive the Financial Crunch of an Illness? 2
...scientists from British Cardiac Society, the Briti...e Primary Care Cardiovascular Society // and the ...idelines for preventing cardiovascular risks of he.... The new guidelines is drafted to reduce the risk...
...tish Medical Journal it was said that people in Lo.../ . Money cannot bring you all the comforts and h...g the relationships that a happy and long life can...als usually get richer during their lifetimes – bu...
... Health & Science University and the University of...ct molecular mixture present in male-emitted phero...ity and increased aggression) dictates the sexual ...ompetitors and influences the female elephants mat...
...robably rosy picture of coma patients' survival an...s for viewers // , says a study. Tracking storylin...hers found that soap opera patients were far more ...e. And they were also much more likely to emerge u...
Other Medicine News:Health News:Happiness Is Not Attained By A Wealthy Life But By A Healthy One. 2Health News:The Chemistry Of Sexual Attraction Between Male And Female Elephants 2
(Date:10/3/2008)... REYKJAVIK, Iceland, Oct. 3 /PRNewswire-FirstCall/...ed the filing of an investigational new drug,(IND)...molecule modulator,of phosphodiesterase 4 (PDE4), ...e compound is being developed as a new and potenti...y loss and cognitive deficits associated,with Alzh...
(Date:10/2/2008)...The Study Will Compare the Results of Rosetta Geno...hich Differentiates Squamous From non Squamous ...tic Methods, A Test Based on the miRview(TM) Techn...olumbia University,s High Complexity Molecular Pat...Year, Rosetta Genomics is Expecting to Launch miR...
(Date:10/2/2008)... GOTEBORG, Sweden, October 2 /- Calab... dose study in xerostomia ("dry mouth"),patients h...studied in 45,dry mouth patients between the ages ...ct a dose for evaluation in a succeeding Phase III... the cholinesterase inhibitor,physostigmine. It is...
(Date:10/2/2008)... Data Indicate Dual Modes of Action and Synergy ...stCall/ -- Access Pharmaceuticals, Inc.,(OTC Bulle...clinical,studies on Angiolix showing that by block...nic effect as well as a direct anti-proliferative ... of human breast cancer (MX-1),Angiolix had a sig...
Breaking Medicine Technology:deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 2deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 3deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 4deCODE Files IND for DG071, a Novel PDE4 Modulator Being Developed for Alzheimer's and Other Cognitive Disorders 5Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 2Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 3Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 4Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics' miRview(TM) Squamous Assay 5Xalieve(TM) Gains Momentum as Calabar AB Launches a Phase II Repeated Dose Study in Dry Mouth Patients 2Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody 2Access Pharmaceuticals Presents New Data on the Company's Angiolix(R) Therapeutic Monoclonal Antibody 3Pancreatic Cancer Biomarkers Found 21825 1Pancreatic Cancer Biomarkers Found 21825 2Specific location of the TRAF1 C5 gene associated with multiple autoimmune diseases 21822 1Specific location of the TRAF1 C5 gene associated with multiple autoimmune diseases 21822 230 percent RA patients refractory to anti TNFs achieve disease remission with tocilizumab plus metho 21819 130 percent RA patients refractory to anti TNFs achieve disease remission with tocilizumab plus metho 21819 2Disc Motion Technologies Announces First Human Implants of True TSMS 28TM 29 Device 2425 1Disc Motion Technologies Announces First Human Implants of True TSMS 28TM 29 Device 2425 2
...HMOND, Va.--(BUSINESS WIRE)--May 3, 2007 - Insmed ...s from a Phase II,investigator-sponsored study of ...otonic muscular dystrophy (DM1)., Preliminary resu...University of Rochester School of Medicine and Den...oses of IPLEX up to 1,mg/kg/day in six patients me...
...ding Symbol: QPT: TSX Venture Exchange, EDMONTON, ...Tech,Inc. ("Quest" or the "Company") Quest is plea...opment of SL052 for the treatment,of prostate canc...of cancer death in,American men with approximately...rent therapeutic modalities for localized prostate...
Other Medicine Technology:Insmed Announces Promising Results From IPLEX Phase II Myotonic,Muscular Dystrophy Clinical Study 2Insmed Announces Promising Results From IPLEX Phase II Myotonic,Muscular Dystrophy Clinical Study 3Insmed Announces Promising Results From IPLEX Phase II Myotonic,Muscular Dystrophy Clinical Study 4Quest PharmaTech's Prostate Cancer Program Update 2Quest PharmaTech's Prostate Cancer Program Update 3
Bacon Bone Rongeur
Schell Rongeur
Zaufal-Jansen Ronguer
Ruskin Mini-Bone Rongeur
Medicine Products: